Callio Therapeutics, a Seattle, WA- and Singapore-based biotechnology company focused on developing multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, raised US$187M in Series A funding.
The round was led by Frazier Life Sciences with participation from Jeito Capital alongside other life sciences investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI.
The company intends to use the funds to expand operations and its development efforts.
Callio Therapeutics is focused on developing multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is providing new multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to optimize therapeutic benefit. Its lead program is a HER2-targeted dual-payload ADC.
The founding Callio Therapeutics management team comprises:
- Piers Ingram, PhD, Chief Executive Officer
- Jerome Boyd-Kirkup, PhD, Chief Scientific Officer
- Naomi Hunder, MD, Chief Medical Officer
- Angèle Maki, PhD, Chief Business Officer
In conjunction with the financing, Callio Therapeutics has entered into an exclusive worldwide license agreement with Hummingbird Bioscience for its multi-payload ADC platform in oncology, and associated intellectual property and pipeline assets, in exchange for equity, potential milestone payments and royalties.
FinSMEs
03/03/2025